In vivo intensification of free-radical oxidation of low-density lipoproteins in the plasma of patients with coronary heart disease treated with [beta]-hydroxy-[beta]-methylglutaryl coenzyme A reductase inhibitor pravastatin and inhibition of lipid peroxidation with ubiquinone Q10

Pravastatin, an inhibitor of β-hydroxy-β-methylglutaryl coenzyme A reductase, the key enzyme of cholesterol biosynthesis,in vivo elevated the content of primary and secondary products of free-radical oxidation in low-density lipoproteins in patients with coronary heart disease, while combined treatment with pravastatin and ubiquinone Q^sub 10^ sharply decreased this parameter. Ubiquinone Q^sub 10^ prevented pravastatin-induced inhibition of antioxidant enzymes superoxide dismutase and lipid peroxidase utilizing reactive oxygen species in the blood. These data indicate that ubiquinone Q^sub 10^ would be appropriate for use in combination with statins, inhibitors of β-hydroxy-β-methylglutaryl coenzyme A reductase, for the therapy of patients with coronary heart disease.[PUBLICATION ABSTRACT]